Nwamaka Emeruem
Psychiatric/Mental Health · Vancouver, WANPI 1508366642
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Corium, LLC$939
- Alkermes, Inc.$866
- Johnson & Johnson$827
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$701
- Takeda Pharmaceuticals U.S.A., Inc.$622
- plus $2K from 14 others
What the payments were for
- Food & beverage$7,759100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 81 | $1,639 |
| Corium, LLC | 37 | $939 |
| Alkermes, Inc. | 41 | $866 |
| Johnson & Johnson | 29 | $827 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $701 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $622 |
| Otsuka America Pharmaceutical, Inc. | 17 | $402 |
| Axsome Therapeutics, Inc. | 7 | $380 |
| Teva Pharmaceuticals USA, Inc. | 5 | $293 |
| Lundbeck LLC | 14 | $225 |
| Sunovion Pharmaceuticals Inc. | 14 | $211 |
| Neurocrine Biosciences, Inc. | 8 | $182 |
| Eisai Inc. | 9 | $141 |
| Neos Therapeutics, LP | 5 | $107 |
| Idorsia Pharmaceuticals US Inc | 4 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $72 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Merck | 2 | $32 |
| Almatica Pharma LLC | 1 | $21 |
| Indivior Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$411
- LYBALVI$400
- Auvelity$246
- VRAYLAR$235
- CAPLYTA$229
- Austedo XR$124
- AUSTEDO$110
- SPRAVATO$105
- ARISTADA INITIO$103
How this compares
$7,778 in reported general payments places this provider in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 12 | $17,994 |
| TrintellixVortioxetine Hydrobromide | 18 | $9,843 |
| Divalproex Sodium | 15 | $639 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $436 |
| Gabapentin | 16 | $322 |
| Zolpidem Tartrate ErZolpidem Tartrate | 12 | $166 |
| Trazodone Hcl | 13 | $162 |
| Quetiapine Fumarate | 15 | $123 |
| Lithium Carbonate ErLithium Carbonate | 16 | $57 |
| Zolpidem Tartrate | 13 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $402 | $17,99412 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $622 | $9,84318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Other psychiatric/mental health in Vancouver
- Brendan RoeVancouver$18K
- Rhonda RowanVancouver$10K
- John JohnsonVancouver$8K
- Hsiangfeng TsaiVancouver$5K
- David CaliffVancouver$4K
- Cailin JarrellVancouver$4K
- Angela CombsRichland$121K
- Ashley McGinnisAuburn$26K
- Courtney YantPuyallup$26K
- Dawn MasonSpokane$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.